Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Vitamin D for Chronic Sinusitis

This study has been completed.
Information provided by (Responsible Party):
University of Chicago Identifier:
First received: November 3, 2009
Last updated: August 25, 2016
Last verified: August 2016
The purpose of this study is to examine if vitamin D improves the symptoms of chronic sinusitis.

Condition Intervention
Chronic Sinusitis
Dietary Supplement: vitamin D placebo
Dietary Supplement: Vitamin D

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Clinical Trial of a Novel Immunotherapy for Chronic Sinusitis: Vitamin D

Resource links provided by NLM:

Further study details as provided by University of Chicago:

Primary Outcome Measures:
  • score on the Sinonasal Outcome Test-22 (SNOT-22) [ Time Frame: study onset, mid-point and conclusion ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Quality of life as measured by SF-36 [ Time Frame: At entry and at completion of study ] [ Designated as safety issue: No ]

Enrollment: 30
Study Start Date: November 2009
Study Completion Date: September 2011
Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Placebo pills to take for 12 weeks
Dietary Supplement: vitamin D placebo
12 weeks of placebo
Active Comparator: Vitamin D
Vitamin D supplement for 12 weeks
Dietary Supplement: Vitamin D
12 weeks supplementation based on serum vitamin D levels


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • African American (4 grandparents with AA ancestry)
  • Age>18 years
  • Diagnosis of chronic sinusitis

Exclusion Criteria:

  • Women of childbearing potential not utilizing contraception
  • Subjects with contraindications to vitamin D therapy
  • History of nephrolithiasis, hypercalcemia, sarcoidosis, recent (3 month) hospitalization
  • Use of immunosuppressants/medications that interfere with vitamin D metabolism (e.g., phenytoin and carbamazepine)
  • Malignancy
  • Kidney, gastrointestinal, or liver disorders
  • Immunodeficiency
  • Morbid obesity (BMI>35 kg/m2)
  • Changes to medications for 6 months prior to study entry
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01007799

United States, Illinois
University of Chicago
Chicago, Illinois, United States, 60637
Sponsors and Collaborators
University of Chicago
Principal Investigator: Jayant Pinto, MD University of Chicago
  More Information

Responsible Party: University of Chicago Identifier: NCT01007799     History of Changes
Other Study ID Numbers: 16601A 
Study First Received: November 3, 2009
Last Updated: August 25, 2016
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Chronic Disease
Paranasal Sinus Diseases
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Disease Attributes
Pathologic Processes
Vitamin D
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents processed this record on October 27, 2016